Zobrazeno 1 - 10
of 173
pro vyhledávání: '"J. P. Kleisbauer"'
Publikováno v:
Revista Portuguesa de Pneumologia, Vol 11, Iss 4, Pp 413-415 (2005)
Externí odkaz:
https://doaj.org/article/d03cc1aa963a47f4ae202b254b068fab
Autor:
F. Barlési, C. Gimenez, J.-P. Torre, C. Doddoli, J. Mancini, L. Greillier, F. Roux, J.-P. Kleisbauer
Publikováno v:
Revista Portuguesa de Pneumologia, Vol 11, Iss 2, Pp 187-189 (2005)
Externí odkaz:
https://doaj.org/article/bd7eaaff34d046bdac488566074e104d
Autor:
Ranfaing E, D. Moro, Bernard Milleron, Elisabeth Brambilla, Alain Depierre, D Anthoine, G Garnier, Pierre Fournel, J P Kleisbauer, P. Jacoulet, Frédérique Capron, Alain Rivière, E. Quoix, J P Leclerc, F Massin, Bernard Lebeau, M Zaegel, Jean-Jacques Lafitte
Publikováno v:
Annals of Oncology. 8:1009-1014
Summary Background The aim of this study was to analyze SCLC patients beyond 30 months, particularly their outcome, their way of life, and factors which could influence relapses, second-primary cancers and death. Patients and methods Between January
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::904c33600658701836adae0bf29a7626
https://doi.org/10.1023/a:1008287922285
https://doi.org/10.1023/a:1008287922285
Autor:
P. Carles, Pierre Fournel, M. Marty, K M de Bruijn, A. Vergnenegre, Loria-Kanza Y, J-P Kleisbauer, C. Simonetta
Publikováno v:
Anti-Cancer Drugs. 6:15-21
The purpose of this study was to evaluate and compare the antiemetic effectiveness and tolerability of Navoban® (tropisetron) and Zofran® (ondansetron) following high-dose (≥ 50 mg/m2) cisplatin chemotherapy. In a randomised, multi-centre, double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::713aa0947b03421db9842ef3185e3801
https://doi.org/10.1097/00001813-199502001-00004
https://doi.org/10.1097/00001813-199502001-00004
Autor:
F. Bonnaud, Arnaud A, A. Taytard, R. Poirier, P. Thomas, D Touron, R. Targhetta, J. Vergeret, J. P. Kleisbauer, P. Balmes
Publikováno v:
American Journal of Clinical Oncology. 13:S20-23
Pirarubicin (THP) (Roger Bellon Laboratory, France) is a new anthracycline under clinical development. In order to assess the efficacy and toxicity of the drug in small-cell lung carcinoma (SCLC), we have undertaken this trial in front-line therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7770327f1571a50e863d3df9909301a
https://doi.org/10.1097/00000421-199012001-00006
https://doi.org/10.1097/00000421-199012001-00006
Autor:
H, Ratsimanohatra, F, Barlesi, C, Doddoli, S, Robitail, C, Gimenez, J P, Kleisbauer, P, Astoul
Publikováno v:
Revue des maladies respiratoires. 22(2 Pt 1)
The treatment of bone metastasis from lung cancer is palliative in nature with elimination of pain being the primary goal. Management is based on pharmacologicalmethods (steroids, morphine, and pamidronate) and radiotherapy. However, other treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5bc3cf4ccf0185a825a368d09d6d35f
https://pubmed.ncbi.nlm.nih.gov/16092169
https://pubmed.ncbi.nlm.nih.gov/16092169
Autor:
P, Thomas, G, Robinet, S, Gouva, P, Fournel, H, Léna, H, Le Caer, M, Perol, H, Berard, P, Bombaron, A, Vergnenegre, J P, Kleisbauer
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 51(1)
To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer (NSCLC).A randomized phase II study was conducted by the Groupe Français de Pneumo-Cancéro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a074adf001e260e0e5a9145f8253c4c0
https://pubmed.ncbi.nlm.nih.gov/16310886
https://pubmed.ncbi.nlm.nih.gov/16310886
Autor:
C, Tchouhadjian, F, Barlesi, C, Doddoli, B, Escarguel, P, Thomas, T, Witjas, P, Astoul, J P, Kleisbauer
Publikováno v:
Revue des maladies respiratoires. 21(6 Pt 1)
The diagnosis and treatment of the neurological paraneoplastic syndromes associated with lung cancer can pose a challenge both to general physicians and neurologists as well as pulmonologists.A 53 year-old heavy smoker presented with a Lambert-Eaton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f8398106a6f382767e366713da2a1428
https://pubmed.ncbi.nlm.nih.gov/15767964
https://pubmed.ncbi.nlm.nih.gov/15767964
Publikováno v:
Revue des maladies respiratoires. 21(3 Pt 1)
Paraneoplastic syndromes sometimes lead to the discovery of an intrathoracic tumour, notably small cell lung cancer (SCLC).We report the case of a patient presenting with a paraneoplastic syndrome characterised by disordered higher functions and conv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ca9d340d961257243d085560774d5559
https://pubmed.ncbi.nlm.nih.gov/15292854
https://pubmed.ncbi.nlm.nih.gov/15292854
Autor:
A, Vergnenègre, C, Daniel, H, Léna, P, Fournel, J P, Kleisbauer, H, Le Caer, J, Letreut, D, Paillotin, M, Pérol, E, Bouchaert, P M, Preux, G, Robinet
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 47(3)
The most satisfactory treatment for patients with locally advanced non-small-cell lung cancer (NSCLC) is combination chemotherapy-radiotherapy (CT-RT). The optimal treatment modalities remain to be determined.We conducted a multicenter phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::48e795e557816d85cfc7e2614bf43d6d
https://pubmed.ncbi.nlm.nih.gov/15713523
https://pubmed.ncbi.nlm.nih.gov/15713523